Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide regimen in relapsed and refractory multiple myeloma
ChiCTR2100047616Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jul 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Very Good Partial Response Rate and Complete Response Rate. Started Jul 2021; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2100047616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047616.